Danaher Corporation $DHR Shares Sold by Neville Rodie & Shaw Inc.

Neville Rodie & Shaw Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 41.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,482 shares of the conglomerate’s stock after selling 21,080 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Danaher were worth $5,845,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. Vanguard Group Inc. boosted its position in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after buying an additional 788,499 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after acquiring an additional 612,154 shares during the period. Geode Capital Management LLC grew its stake in shares of Danaher by 0.6% in the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after purchasing an additional 81,670 shares in the last quarter. Norges Bank acquired a new position in shares of Danaher during the second quarter valued at $1,979,503,000. Finally, Generation Investment Management LLP raised its stake in shares of Danaher by 56.2% during the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,248 shares of company stock worth $6,609,663 in the last quarter. 11.20% of the stock is owned by company insiders.

Danaher Trading Down 2.4%

Shares of NYSE:DHR opened at $226.70 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market capitalization of $160.13 billion, a price-to-earnings ratio of 46.74, a PEG ratio of 4.39 and a beta of 0.89. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The company has a 50 day moving average price of $218.51 and a 200 day moving average price of $205.90.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.71 earnings per share. On average, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio is currently 26.39%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research report on Tuesday, September 2nd. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Bank of America dropped their target price on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Wells Fargo & Company set a $240.00 price target on Danaher in a research note on Monday. Finally, Redburn Partners set a $220.00 price target on Danaher in a research report on Wednesday, October 8th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $247.21.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.